Home › Lung Cancer › NCT06080061
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
RecruitingPhase 1
Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy * ECOG performance status of 0-2 * Age ≥ 18 years old * Ability to understand and the willingness to personally sign the written IRB approved informed consent document * Estimated life expectancy of 12 weeks or longer Exclusion Criteria: * Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist * Age \< 18 years old * Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree * Diagnosis of interstitial pulmonary fibrosis * Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields
About the study
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
What is being tested
- Hypofractionated accelerated radiation therapy (radiation)
Sponsor: Stanford University · Participants: 45 · Started: Oct 25, 2023
Contact the study team
- Aastha Dubey · Phone: 650-725-2084
- Sonya Boyd · Phone: 650-723-2732
Official record on ClinicalTrials.gov — NCT06080061
Locations in the U.S.
| California | Stanford University, Palo Alto Stanford Cancer Center South Bay, San Jose |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.